Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737633 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
A Phase 2 study, sponsored by VIVUS.
- Terminated
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00737633 is a Phase 2 study that was terminated before completion, run by VIVUS. The registered enrollment target is 101 participants.
The verdict
NCT00737633, a Phase 2 study, was terminated before completion, sponsored by VIVUS.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to enroll into this study will receive study drug.
Interventions
- DRUG VI-0521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737633
The ClinicalTrials.gov registry entry for NCT00737633 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VI-0521 is the first listed.
NCT00737633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737633 about?
NCT00737633 is a clinical study titled "Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults". This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to...
What is the current status of trial NCT00737633?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2008-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00737633?
The interventions under investigation include: VI-0521 (DRUG).
Who is sponsoring clinical trial NCT00737633?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.